Ashish Mukkirwar appointed CFO of Jubilant Pharmova

The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives

Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive

The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses

Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility

The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants

Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics

O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors

Jubilant Pharmova posts consolidated Q2 FY26 PAT at Rs. 120.3 Cr

Jubilant HollisterStier launches new sterile fill & finish line at its Spokane facility in US

The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision

Jubilant Pharmova posts Q4 FY25 consolidated PAT at Rs. 153.6 Cr

Jubilant Pharmova has posted net profit of Rs. 839.4 crores for the Financial Year ended March 31, 2025

FDA issues five observations to Jubilant Pharmova’s Salisbury facility in USA

Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations

USFDA inspection update on Jubilant HollisterStier’s Montreal facility

HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures

USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington

Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding